The Challenge of CMC Regulatory Compliance for Biopharmaceuticals:
"The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls...
Gespeichert in:
1. Verfasser: | |
---|---|
Format: | Elektronisch E-Book |
Sprache: | English |
Veröffentlicht: |
Boston, MA
Springer US
2004
|
Schlagworte: | |
Online-Zugang: | UBR01 Volltext |
Zusammenfassung: | "The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed |
Beschreibung: | 1 Online-Ressource (XXIV, 350 p) |
ISBN: | 9781441991317 |
DOI: | 10.1007/978-1-4419-9131-7 |
Internformat
MARC
LEADER | 00000nmm a2200000zc 4500 | ||
---|---|---|---|
001 | BV046148985 | ||
003 | DE-604 | ||
005 | 00000000000000.0 | ||
007 | cr|uuu---uuuuu | ||
008 | 190906s2004 |||| o||u| ||||||eng d | ||
020 | |a 9781441991317 |9 978-1-4419-9131-7 | ||
024 | 7 | |a 10.1007/978-1-4419-9131-7 |2 doi | |
035 | |a (ZDB-2-SBL)978-1-4419-9131-7 | ||
035 | |a (OCoLC)1119090688 | ||
035 | |a (DE-599)BVBBV046148985 | ||
040 | |a DE-604 |b ger |e aacr | ||
041 | 0 | |a eng | |
049 | |a DE-355 | ||
082 | 0 | |a 615 |2 23 | |
100 | 1 | |a Geigert, John |e Verfasser |4 aut | |
245 | 1 | 0 | |a The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |c by John Geigert |
264 | 1 | |a Boston, MA |b Springer US |c 2004 | |
300 | |a 1 Online-Ressource (XXIV, 350 p) | ||
336 | |b txt |2 rdacontent | ||
337 | |b c |2 rdamedia | ||
338 | |b cr |2 rdacarrier | ||
520 | |a "The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed | ||
650 | 4 | |a Pharmacology/Toxicology | |
650 | 4 | |a Biochemistry, general | |
650 | 4 | |a Pharmacy | |
650 | 4 | |a Biological and Medical Physics, Biophysics | |
650 | 4 | |a Toxicology | |
650 | 4 | |a Biochemistry | |
650 | 4 | |a Pharmacy | |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781461348047 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9780306480409 |
776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |z 9781441991324 |
856 | 4 | 0 | |u https://doi.org/10.1007/978-1-4419-9131-7 |x Verlag |z URL des Erstveröffentlichers |3 Volltext |
912 | |a ZDB-2-SBL | ||
940 | 1 | |q ZDB-2-SBL_2000/2004 | |
999 | |a oai:aleph.bib-bvb.de:BVB01-031529162 | ||
966 | e | |u https://doi.org/10.1007/978-1-4419-9131-7 |l UBR01 |p ZDB-2-SBL |q ZDB-2-SBL_2000/2004 |x Verlag |3 Volltext |
Datensatz im Suchindex
_version_ | 1804180489955704832 |
---|---|
any_adam_object | |
author | Geigert, John |
author_facet | Geigert, John |
author_role | aut |
author_sort | Geigert, John |
author_variant | j g jg |
building | Verbundindex |
bvnumber | BV046148985 |
collection | ZDB-2-SBL |
ctrlnum | (ZDB-2-SBL)978-1-4419-9131-7 (OCoLC)1119090688 (DE-599)BVBBV046148985 |
dewey-full | 615 |
dewey-hundreds | 600 - Technology (Applied sciences) |
dewey-ones | 615 - Pharmacology and therapeutics |
dewey-raw | 615 |
dewey-search | 615 |
dewey-sort | 3615 |
dewey-tens | 610 - Medicine and health |
discipline | Medizin |
doi_str_mv | 10.1007/978-1-4419-9131-7 |
format | Electronic eBook |
fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>03209nmm a2200469zc 4500</leader><controlfield tag="001">BV046148985</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">190906s2004 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781441991317</subfield><subfield code="9">978-1-4419-9131-7</subfield></datafield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1007/978-1-4419-9131-7</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-2-SBL)978-1-4419-9131-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)1119090688</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV046148985</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-355</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615</subfield><subfield code="2">23</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Geigert, John</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The Challenge of CMC Regulatory Compliance for Biopharmaceuticals</subfield><subfield code="c">by John Geigert</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Boston, MA</subfield><subfield code="b">Springer US</subfield><subfield code="c">2004</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (XXIV, 350 p)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">"The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacology/Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry, general</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biological and Medical Physics, Biophysics</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Toxicology</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Biochemistry</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pharmacy</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781461348047</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9780306480409</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="z">9781441991324</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1007/978-1-4419-9131-7</subfield><subfield code="x">Verlag</subfield><subfield code="z">URL des Erstveröffentlichers</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-2-SBL</subfield></datafield><datafield tag="940" ind1="1" ind2=" "><subfield code="q">ZDB-2-SBL_2000/2004</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-031529162</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://doi.org/10.1007/978-1-4419-9131-7</subfield><subfield code="l">UBR01</subfield><subfield code="p">ZDB-2-SBL</subfield><subfield code="q">ZDB-2-SBL_2000/2004</subfield><subfield code="x">Verlag</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
id | DE-604.BV046148985 |
illustrated | Not Illustrated |
indexdate | 2024-07-10T08:36:35Z |
institution | BVB |
isbn | 9781441991317 |
language | English |
oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-031529162 |
oclc_num | 1119090688 |
open_access_boolean | |
owner | DE-355 DE-BY-UBR |
owner_facet | DE-355 DE-BY-UBR |
physical | 1 Online-Ressource (XXIV, 350 p) |
psigel | ZDB-2-SBL ZDB-2-SBL_2000/2004 ZDB-2-SBL ZDB-2-SBL_2000/2004 |
publishDate | 2004 |
publishDateSearch | 2004 |
publishDateSort | 2004 |
publisher | Springer US |
record_format | marc |
spelling | Geigert, John Verfasser aut The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert Boston, MA Springer US 2004 1 Online-Ressource (XXIV, 350 p) txt rdacontent c rdamedia cr rdacarrier "The greater our knowledge increases, the more our ignorance unfolds. " U. S. President John F. Kennedy, speech, Rice University, September 12, 1962 My primary purpose for writing this book was much more than to provide another information source on Chemistry, Manufacturing & Controls (CMC) that would rapidly become out of date. My primary purpose was to provide insight and practical suggestions into a common sense business approach to manage the CMC regulatory compliance requirements for biopharmaceuticals. Such a common sense business approach would need (1) to be applicable for all types of biopharmaceutical products both present and future, (2) to address the needs of a biopharmaceutical manufacturer from the beginning to the end of the clinical development stages and including post market approval, and (3) to be adaptable to the constantly changing CMC regulatory compliance requirements and guidance. Trying to accomplish this task was a humbling experience for this author! In Chapter 1, the CMC regulatory process is explained, the breadth of products included under the umbrella ofbiopharmaceuticals are identified, and the track record for the pharmaceutical and biopharmaceutical industry in meeting CMC regulatory compliance is discussed. In Chapter 2, while there are many CMC commonalities between biopharmaceuticals and chemically-synthesized pharmaceuticals, the significant differences in the way the regulatory agencies handle them are examined and the reasons for why such differences are necessary is discussed. Also, the importance of CMC FDA is stressed Pharmacology/Toxicology Biochemistry, general Pharmacy Biological and Medical Physics, Biophysics Toxicology Biochemistry Erscheint auch als Druck-Ausgabe 9781461348047 Erscheint auch als Druck-Ausgabe 9780306480409 Erscheint auch als Druck-Ausgabe 9781441991324 https://doi.org/10.1007/978-1-4419-9131-7 Verlag URL des Erstveröffentlichers Volltext |
spellingShingle | Geigert, John The Challenge of CMC Regulatory Compliance for Biopharmaceuticals Pharmacology/Toxicology Biochemistry, general Pharmacy Biological and Medical Physics, Biophysics Toxicology Biochemistry |
title | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |
title_auth | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |
title_exact_search | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |
title_full | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert |
title_fullStr | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert |
title_full_unstemmed | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals by John Geigert |
title_short | The Challenge of CMC Regulatory Compliance for Biopharmaceuticals |
title_sort | the challenge of cmc regulatory compliance for biopharmaceuticals |
topic | Pharmacology/Toxicology Biochemistry, general Pharmacy Biological and Medical Physics, Biophysics Toxicology Biochemistry |
topic_facet | Pharmacology/Toxicology Biochemistry, general Pharmacy Biological and Medical Physics, Biophysics Toxicology Biochemistry |
url | https://doi.org/10.1007/978-1-4419-9131-7 |
work_keys_str_mv | AT geigertjohn thechallengeofcmcregulatorycomplianceforbiopharmaceuticals |